Physician profile
Christopher Bryan Tchou
NPI 1295224590
$1,702.82
in general payments reported to CMS, 2019-2025
19 companies · $453 in 2025
The $453 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $114 · 2022: $249 · 2023: $472 · 2024: $415 · 2025: $453.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,340.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,339.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $402.99 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $330.74 | 2022-2025 | Ubrelvy, Qulipta, Vraylar |
| Novo Nordisk INC | $315.96 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Corcept Therapeutics | $114.41 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $110.61 | 2022-2025 | Farxiga, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $83.64 | 2023-2025 | |
| Amgen INC. | $61.37 | 2024-2025 | Repatha, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.79 | 2024-2025 | Jardiance |
| Exact Sciences Corporation | $34.00 | 2025 | The Cologuard Plus Collection Kit |
| Phathom Pharmaceuticals, INC. | $30.00 | 2023-2024 | Voquezna |
| Abbott Laboratories | $24.58 | 2024 | Freestyle Libre 3 |
| Pfizer INC. | $23.96 | 2025 | |
| Dexcom, INC. | $23.92 | 2024 | Dexcom G6 Transmitter |
| Phadia US INC. | $20.06 | 2024 | Immunocap |
| Tolmar, INC. | $20.06 | 2025 | Jatenzo |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $14.44 | 2023 | Arexvy, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.39 | 2024 | Xifaxan |
| Idorsia Pharmaceuticals US INC | $13.65 | 2023 | Quviviq |
| Paratek Pharmaceuticals, INC. | $13.25 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Tchou listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.